Euregen Biopharma patents new SOS1/KRAS G12C interaction inhibitors for cancer
Jan. 12, 2024
Euregen Biopharma Co. Ltd. has disclosed son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.